A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney ...

A research team with Professor Neha Kamat used synthetic liposomes and bacterial extracts to generate immune responses ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

AI also supports reverse vaccinology, where pathogen genomes are computationally analyzed to identify immunogenic regions ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

Now, mRNA vaccines can be quickly created against different antigenic targets by changing the mRNA sequence, and companies are looking beyond COVID-19 at other infectious diseases, including ...

The complaint, filed by a coalition of medical professional groups, also said candidates would not be allowed to join if they previously criticized Trump.

The researchers added that with routine vaccination declining and also impacted by cuts to the US' foreign aid, the study ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Partial immunity from COVID in residents early in the pandemic and infection-prevention measures may explain the findings, ...